Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) Price Target at $33.83

Shares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $33.83.

SLN has been the subject of a number of analyst reports. Chardan Capital decreased their price objective on shares of Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a report on Friday, May 9th. HC Wainwright reissued a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th. The Goldman Sachs Group decreased their price objective on Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a research report on Friday, May 9th. BMO Capital Markets cut their price target on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Finally, Morgan Stanley dropped their target price on Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new stake in shares of Silence Therapeutics in the 4th quarter valued at approximately $26,000. GAMMA Investing LLC raised its position in Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock worth $42,000 after acquiring an additional 5,233 shares in the last quarter. Barclays PLC lifted its stake in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Silence Therapeutics during the 4th quarter worth approximately $69,000. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock worth $74,000 after acquiring an additional 6,098 shares during the last quarter. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Price Performance

Shares of Silence Therapeutics stock traded up $0.36 on Tuesday, hitting $4.37. 281,395 shares of the company's stock traded hands, compared to its average volume of 299,209. The firm's 50-day moving average price is $3.33 and its two-hundred day moving average price is $6.18. The stock has a market capitalization of $130.79 million, a PE ratio of -2.78 and a beta of 1.20. Silence Therapeutics has a one year low of $1.97 and a one year high of $24.38.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). The company had revenue of $0.14 million for the quarter, compared to the consensus estimate of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. On average, analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.